294 413

Cited 0 times in

Impact of everolimus on survival after liver transplantation for hepatocellular carcinoma

DC Field Value Language
dc.contributor.author김명수-
dc.contributor.author김순일-
dc.contributor.author김현정-
dc.contributor.author이재근-
dc.contributor.author주동진-
dc.contributor.author최기홍-
dc.contributor.author최진섭-
dc.contributor.author한대훈-
dc.date.accessioned2021-11-19T01:40:10Z-
dc.date.available2021-11-19T01:40:10Z-
dc.date.issued2021-10-
dc.identifier.issn2287-2728-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/185974-
dc.description.abstractBackground/aims: This study aimed to investigate whether everolimus (EVR) affects long-term survival after liver transplantation (LT) in patients with hepatocellular carcinoma (HCC). Methods: The data from 303 consecutive patients with HCC who had undergone LT from January 2012 to July 2018 were retrospectively reviewed. The patients were divided into two groups: 1) patients treated with EVR in combination with calcineurin inhibitors (CNIs) (EVR group; n=114) and 2) patients treated with CNI-based therapy without EVR (non-EVR group; n=189). Time to recurrence (TTR) and overall survival (OS) after propensity score (PS) matching were compared between the groups, and prognostic factors for TTR and OS were evaluated. Results: The EVR group exhibited more aggressive tumor biology than the non-EVR group, such as a higher number of tumors (P=0.003), a higher prevalence of microscopic vascular invasion (P=0.017) and exceeding Milan criteria (P=0.029). Compared with the PS-matched non-EVR group, the PS-matched EVR group had significantly better TTR (P<0.001) and OS (P<0.001). In multivariable analysis, EVR was identified as an independent prognostic factor for TTR (hazard ratio [HR], 0.248; P=0.001) and OS (HR, 0.145; P<0.001). Conclusion: Combined with CNIs, EVR has the potential to prolong long-term survival in patients undergoing LT for HCC. These findings warrant further investigation in a well-designed prospective study.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherKorean Association for the Study of the Liver-
dc.relation.isPartOfCLINICAL AND MOLECULAR HEPATOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleImpact of everolimus on survival after liver transplantation for hepatocellular carcinoma-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorIncheon Kang-
dc.contributor.googleauthorJae Geun Lee-
dc.contributor.googleauthorSung Hoon Choi-
dc.contributor.googleauthorHyun Jeong Kim-
dc.contributor.googleauthorDai Hoon Han-
dc.contributor.googleauthorGi Hong Choi-
dc.contributor.googleauthorMyoung Soo Kim-
dc.contributor.googleauthorJin Sub Choi-
dc.contributor.googleauthorSoon Il Kim-
dc.contributor.googleauthorDong Jin Joo-
dc.identifier.doi10.3350/cmh.2021.0038-
dc.contributor.localIdA00424-
dc.contributor.localIdA00649-
dc.contributor.localIdA06066-
dc.contributor.localIdA03068-
dc.contributor.localIdA03948-
dc.contributor.localIdA04046-
dc.contributor.localIdA04199-
dc.contributor.localIdA04273-
dc.relation.journalcodeJ00557-
dc.identifier.eissn2287-285X-
dc.identifier.pmid34293849-
dc.subject.keywordHepatocellular carcinoma-
dc.subject.keywordImmunosuppression-
dc.subject.keywordLiver transplantation-
dc.subject.keywordRecurrence-
dc.subject.keywordSurvival-
dc.contributor.alternativeNameKim, Myoung Soo-
dc.contributor.affiliatedAuthor김명수-
dc.contributor.affiliatedAuthor김순일-
dc.contributor.affiliatedAuthor김현정-
dc.contributor.affiliatedAuthor이재근-
dc.contributor.affiliatedAuthor주동진-
dc.contributor.affiliatedAuthor최기홍-
dc.contributor.affiliatedAuthor최진섭-
dc.contributor.affiliatedAuthor한대훈-
dc.citation.volume27-
dc.citation.number4-
dc.citation.startPage589-
dc.citation.endPage602-
dc.identifier.bibliographicCitationCLINICAL AND MOLECULAR HEPATOLOGY, Vol.27(4) : 589-602, 2021-10-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.